Therefore, the purpose of PALTAN was to evaluate the pCR rate following neoadjuvant treatment with palbociclib plus letrozole plus trastuzumab in patients with ER+/HER2+ early breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.